阿米卡星水合物 | 1257517-67-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 阿米卡星水合物
• 英文名称: Amikacin hydrate
• 英文别名: (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide;hydrate
• CAS: 1257517-67-1
• 化学式: C22H45N5O14
• 分子量: 603.6
• InChiKey: DTSOZYYWEZJFSS-XTHCGPPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -9.25
• 重原子数：
  41
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  333
• 氢给体数：
  14
• 氢受体数：
  18

文献信息

• METHODS AND COMPOSITIONS FOR TREATING INFECTION
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20150238473A1

  公开（公告）日：2015-08-27

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• MOLECULAR SENSOR AND METHODS OF USE THEREOF
  申请人：YEDA RESEARCH AND DEVELOPMENT CO. LTD.

  公开号：US20150276753A1

  公开（公告）日：2015-10-01

  The present invention is directed to fluorescent molecular sensor based on Thiazole Orange for protein detection. Interaction of the protein target with the molecular sensors of this invention results in a significant increase in the fluorescence emission. The generation of light output signal enables one to detect protein biomarkers associated with different diseases or detecting the protein of interest also in living cells.

  本发明涉及一种基于Thiazole Orange的荧光分子传感器，用于蛋白质检测。本发明的分子传感器与蛋白质靶标的相互作用导致荧光发射显著增加。光输出信号的产生使得人们能够检测与不同疾病相关的蛋白质生物标志物或者在活细胞中检测感兴趣的蛋白质。
• NOVEL METHODS FOR RAPID DRUG SUSCEPTIBILITY TESTING AND DRUG SCREENS FOR GROWING AND NON-GROWING CELLS OF PROKARYOTIC AND EUKARYOTIC ORIGIN
  申请人：Zhang, Ying

  公开号：EP3321371A1

  公开（公告）日：2018-05-16

  The presently disclosed subject matter provides methods, compositions, and kits for extremely rapid assessment of drug susceptibility of growing as well as non-growing cells of prokaryotic and also eukaryotic origins, without the need for organism growth, which is in contrast to the current growth-dependent methods.This growth-independent new methodology achieves extremely rapid drug susceptibility testing results previously not possible. Methods for rapidly identifying compounds with inhibitory activity against both growing and non-growing cells in real-time continuous manner with previously unachievable efficiency in drug screens using the novel methodology are also provided. Cell cultures are incubated with a drug or test agent and with a staining mixture containing a first fluorescent dye indicative the emission of which is indicative of live cells (e.g. SYBR Green I) and a second fluorescent dye indicative emitting a different color, the emission of which is indicative of dead cells (e.g. Propidium iodide). The ratio of the intensities of the emitted fluorescence of the dyes is indicative of the percentage live and dead cells in the culture.

  与目前依赖生长的方法相比，本公开的主题提供了无需生物体生长即可对原核和真核的生长和非生长细胞的药物敏感性进行极快速评估的方法、组合物和试剂盒，这种不依赖生长的新方法实现了以前无法实现的极快速药物敏感性测试结果。此外，还提供了实时连续地快速鉴定对生长细胞和非生长细胞具有抑制活性的化合物的方法，这种方法在使用新方法进行药物筛选时具有以前无法实现的效率。细胞培养物与药物或测试剂以及染色混合物一起孵育，染色混合物含有第一种荧光染料指示剂，其发射的荧光指示剂可指示活细胞（如 SYBR 绿 I）和第二种发出不同颜色的荧光染料指示剂，其发射的荧光指示剂可指示死细胞（如碘化丙啶）。染料发射荧光强度的比值表示培养液中活细胞和死细胞的百分比。
• INHIBITORS FOR METHYLATION-RELATED ENZYMES HAT1 AND KAT8
  申请人：MIURA, Norimasa

  公开号：EP3369434A1

  公开（公告）日：2018-09-05

  The purpose of the present invention is to obtain novel therapeutic drugs for malignant tumors, methods for producing a stem cell, or DNA damage-ameliorating agents, etc., wherein a HAT1 and KAT8 inhibitor is used; a kit containing a HAT1 inhibitor and a KAT8 inhibitor may be used; a composition comprising a HAT1 inhibitor, wherein the HAT1 inhibitor is used in combination with a KAT8 inhibitor, may be used; or a composition comprising a KAT8 inhibitor, wherein the KAT8 inhibitor is used in combination with a HAT1 inhibitor, may be used._

  本发明的目的是获得恶性肿瘤的新型治疗药物、产生干细胞的方法或DNA损伤改善剂等、其中可以使用HAT1和KAT8抑制剂；可以使用含有HAT1抑制剂和KAT8抑制剂的试剂盒；可以使用含有HAT1抑制剂的组合物，其中HAT1抑制剂与KAT8抑制剂结合使用；或者可以使用含有KAT8抑制剂的组合物，其中KAT8抑制剂与HAT1抑制剂结合使用。
• PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF FLAVIVIRUS INFECTIOUS DISEASE
  申请人：Lemonex Inc.

  公开号：EP3785718A1

  公开（公告）日：2021-03-03

  The present invention provides a pharmaceutical composition including at least one of gentamicin sulfate, netilmicin, tobramycin, paromomycin, amikacin, capreomycin, trifluoroperazine, dihydrostreptomycin, hydroxychloroquine, thioridazine HCl, efavirenz, miltefosine, nystatin, micafungin, bleomycin, resminostat, montelukast, norfloxacin, nedaplatin and cephalothin, which can exhibit excellent growth inhibition or killing effects of various species of flavivirus genus.

  本发明提供了一种药物组合物，包括硫酸庆大霉素、奈替米星、妥布霉素、帕罗霉素、阿米卡星、卡普霉素、三氟哌嗪、双氢链霉素、羟氯喹、盐酸硫利达嗪、依非韦林、米替福辛、奈司他丁、米卡芬净、博来霉素、雷米诺司他、孟特鲁司特、诺氟沙星、奈达铂中的至少一种、efavirenz, miltefosine, nystatin, micafungin, bleomycin, resminostat, montelukast, norfloxacin, nedaplatin 和 cephalothin。